Abecma market forecast points to faster CAR T adoption through 2035

The Business Research Company says the Abecma market is set to keep growing through 2035 as multiple myeloma cases rise, CAR T-cell therapy use expands and manufacturing improves. North America is expected to remain the largest regional market in 2025, with new report tools aimed at helping companies track opportunities.

Why it matters: - Abecma sits in a fast-growing corner of oncology tied to CAR T-cell therapy and multiple myeloma treatment. - Rising disease burden and wider treatment access could expand demand for personalized cell therapies over the next decade. - The forecast matters to drugmakers, oncology centers and investors watching the shift toward advanced cancer care.

What happened: - The Business Research Company published its Abecma Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 1, 2026. - The report says the Abecma market is being driven by clinical results from CAR T therapies, a higher incidence of multiple myeloma, regulatory approvals and broader use of cell therapies in oncology centers. - The company also published a free sample of the report and the full report online: Free sample and the full report.

The details: - Abecma, or idecabtagene vicleucel, is a CAR T-cell therapy for relapsed or refractory multiple myeloma. - The therapy removes a patient’s T cells, genetically engineers them and returns them to target malignant plasma cells. - The report says future growth could come from use in earlier disease stages, improved manufacturing, higher oncology investment, broader patient eligibility and next-generation CAR T therapies. - Key trends in the forecast include growing uptake of CAR T-cell treatments, more advanced cell-based oncology options, personalized cancer therapies, increased use in refractory multiple myeloma and innovations in autologous cell processing. - The report says North America is expected to remain the largest regional market for Abecma in 2025. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The American Cancer Society projected 35,780 new U.S. multiple myeloma cases in 2024, up from 34,470 in 2022.

Between the lines: - The market outlook reflects a broader oncology trend: therapies that once served late-stage patients are moving earlier in the treatment pathway. - The emphasis on manufacturing, eligibility expansion and next-generation CAR T suggests that growth depends not only on clinical demand but also on operational scale and access. - North America’s lead likely reflects stronger treatment adoption, infrastructure and reimbursement conditions than many other regions.

What's next: - The report points to continued expansion as CAR T adoption spreads and multiple myeloma incidence rises. - Future gains will likely hinge on whether manufacturers can lower complexity, expand capacity and widen the patient pool. - The Business Research Company says the 2026 report tools are designed to help track market opportunities and regional hotspots over time.

The bottom line: - Abecma’s market story is no longer just about one therapy; it is about the broader commercialization of CAR T treatment in multiple myeloma and the infrastructure needed to support it.